Latest Onyx Pharmaceuticals Inc. Stories
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significant improvement in overall survival. This is the result...
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss third quarter 2011 financial results, as well as provide a general business overview on Wednesday, November 2, 2011, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the third quarter ended September 30, 2011 will be released earlier that day. Interested parties may access a...
SAN FRANCISCO, Oct. 12, 2011 /PRNewswire/ -- Today Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and Bayer HealthCare restructured their partnership for the global development and marketing of Nexavar® (sorafenib) tablets and entered into a new agreement related to regorafenib, a late-stage oncology compound. Under the terms of the agreements, regorafenib is a Bayer compound, and Bayer will have the final decision-making authority for global development and commercialization. Onyx will...
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has completed the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval process for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. In addition, Onyx has requested priority review of the application, which reduces...
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at two healthcare conferences in September. Baird's 2011 Health Care ConferenceOnyx will present at Baird's 2011 Health Care Conference on Wednesday, September 7, 2011 at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time). Stifel Nicolaus Healthcare Conference 2011Subsequently, Onyx will present at the Stifel Nicolaus Healthcare Conference 2011 on...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has appointed Helen Torley, M.B. Ch. B., M.R.C.P., as Executive Vice President and Chief Commercial Officer. In her role, Dr. Torley will report to N. Anthony Coles, M.D., President and Chief Executive Officer, and will be responsible for all commercial activities related to Nexavar and the potential launch of carfilzomib, development of the company's European...
SOUTH SAN FRANCISCO, Calif., Aug. 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2011 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/investors/event-calendar It is recommended that listeners log on 15 minutes early in order to register and download any...
SOUTH SAN FRANCISCO, Calif., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the second quarter 2011. Onyx reported a non-GAAP net loss of $27.2 million, or $0.43 per diluted share, for the second quarter 2011 compared to a non-GAAP net income of $2.9 million, or $0.05 per diluted share, for the same period in 2010. Non-GAAP net loss excludes, among other items, adjustments to contingent consideration expense in connection with...
SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation (MMRF) today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor. The Carfilzomib Myeloma Access Program (C-MAP) will include eligible patients in the United States (U.S.) with relapsed and refractory multiple myeloma. Expanded access programs make...
SOUTH SAN FRANCISCO, Calif., July 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss second quarter 2011 financial results, as well as provide a general business overview on Wednesday, August 3, 2011, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the second quarter ended June 30, 2011 will be released earlier that day. Interested parties may access a live...
